FDA Approves New Hydrogel System for Arterial Bleeds
The regulatory agency authorized the Embrace Hydrogel Embolic System to treat peripheral arterial bleeds in smaller vessels.
Updated on Oct. 31, 2026 in Stroke
Live Poll
Do you trust that new medical device approvals adequately prioritize long-term patient safety?
The FDA has granted approval for the Embrace Hydrogel Embolic System to treat peripheral arterial bleeds in vessels measuring 6 mm or less. This medical device utilizes a water-based polyethylene glycol hydrogel to create sustained vessel occlusion.
Why it matters
This approval expands the clinical use of the hydrogel technology, which provides a non-surgical option for managing arterial bleeding. The system is designed to maintain microcatheter access during procedures while eventually liquefying via hydrolysis.
The HALT clinical trial enrolled 130 patients across 22 US sites to evaluate the device. The hydrogel is engineered to liquify via hydrolysis over approximately 11 months following the procedure.
The players
FDA
The United States Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices.
Instylla, Inc.
Headquartered in Burlington, MA, this company specializes in developing medical devices for interventional radiology and vascular embolization.
The details
The Embrace Hydrogel Embolic System forms a rapid, sustained occlusion within the vessel upon delivery. Instylla, Inc. previously secured premarket approval for the device in August 2025 specifically for hypervascular tumor embolization in vessels up to 5 mm in diameter.
Timeline
Instylla was founded in 2017.
The FDA granted initial premarket approval for tumor embolization in August 2025.
The FDA issued approval for peripheral arterial bleeds on October 31, 2026.
The Big Picture
This approval follows the evidence established by the HALT clinical trial to validate the safety of hydrogel-based occlusion. It marks a shift toward specialized, temporary embolic materials in interventional radiology.
Patients requiring treatment for peripheral arterial bleeds may now benefit from this non-surgical hydrogel technology. The procedure allows for sustained occlusion that naturally clears over time, potentially simplifying recovery and future clinical access.
The takeaway
This technology provides a specialized tool for interventional radiologists to manage arterial bleeding with a temporary material. The system offers a refined approach to vessel occlusion by maintaining microcatheter access during procedures.
Further reading
For more information on vascular health, visit our Stroke section.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Do you trust that new medical device approvals adequately prioritize long-term patient safety?
